ARCHIVES

Early-Stage HER2+ Breast Cancer Patients Are At Significant Risk Of Recurrence

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

NCI, NSF fund awards in nanotech training.

September 23, 2005

Long-term Hormonal Therapy Adds No Additional Benefits

September 27, 2013

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

July 30, 1999

National Comprehensive Center Network, Quintiles Oncology, To Collaborate On Trials

March 5, 1999

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012

Moddelmog Steps Down At Komen For the Cure

November 20, 2009